Jeffrey Shuren emphasized recent efforts by FDA’s device center to reduce premarket clinical trial burdens in return for strong postmarket controls during the May 6 inaugural roundtable of the House Energy and Commerce Committee’s “21st Century Cures” initiative.
Shuren also put his support behind clinical trial networks as a strategy to speed data gathering during the session on Capitol Hill, which lawmakers organized to identify
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?